問卷

TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Hematology & Oncology

更新時間:2023-09-19

許瑞峰
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

21Cases

2025-10-01 - 2029-12-31

Active
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
  • Condition/Disease

    Squamous Cell Carcinoma of Head and Neck

  • Test Drug

    Subcutaneous injection Injection Injection Injection Injection

Participate Sites
7Sites

Recruiting7Sites

2025-11-01 - 2031-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

2026-01-01 - 2031-07-31

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

2017-06-01 - 2026-08-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated4Sites

2017-10-01 - 2024-11-07

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2017-07-18 - 2026-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting6Sites

2026-05-01 - 2031-08-06

Phase II/III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2026-06-01 - 2030-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting9Sites

2025-10-23 - 2029-02-15

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2026-02-01 - 2034-11-14

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

1 2 3